BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

348 related articles for article (PubMed ID: 22535375)

  • 1. Integrated epigenomics identifies BMP4 as a modulator of cisplatin sensitivity in gastric cancer.
    Ivanova T; Zouridis H; Wu Y; Cheng LL; Tan IB; Gopalakrishnan V; Ooi CH; Lee J; Qin L; Wu J; Lee M; Rha SY; Huang D; Liem N; Yeoh KG; Yong WP; Teh BT; Tan P
    Gut; 2013 Jan; 62(1):22-33. PubMed ID: 22535375
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oxaliplatin in treatment of the cisplatin-resistant MKN45 cell line of gastric cancer.
    Tozawa K; Oshima T; Kobayashi T; Yamamoto N; Hayashi C; Matsumoto T; Miwa H
    Anticancer Res; 2008; 28(4B):2087-92. PubMed ID: 18751380
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improvement of sensitivity to platinum compound with siRNA knockdown of upregulated genes in platinum complex-resistant ovarian cancer cells in vitro.
    Yanagie H; Hisa T; Ogata A; Miyazaki A; Nonaka Y; Nishihira T; Osada I; Sairennji T; Sugiyama H; Furuya Y; Kidani Y; Takamoto S; Takahashi H; Eriguchi M
    Biomed Pharmacother; 2009 Sep; 63(8):553-60. PubMed ID: 18571892
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epigenetic inactivation of BCL6B, a novel functional tumour suppressor for gastric cancer, is associated with poor survival.
    Xu L; Li X; Chu ES; Zhao G; Go MY; Tao Q; Jin H; Zeng Z; Sung JJ; Yu J
    Gut; 2012 Jul; 61(7):977-85. PubMed ID: 21917650
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gene expression profiling for analysis acquired oxaliplatin resistant factors in human gastric carcinoma TSGH-S3 cells: the role of IL-6 signaling and Nrf2/AKR1C axis identification.
    Chen CC; Chu CB; Liu KJ; Huang CY; Chang JY; Pan WY; Chen HH; Cheng YH; Lee KD; Chen MF; Kuo CC; Chen LT
    Biochem Pharmacol; 2013 Oct; 86(7):872-87. PubMed ID: 23933386
    [TBL] [Abstract][Full Text] [Related]  

  • 6. IGFBP-3 hypermethylation-derived deficiency mediates cisplatin resistance in non-small-cell lung cancer.
    Ibanez de Caceres I; Cortes-Sempere M; Moratilla C; Machado-Pinilla R; Rodriguez-Fanjul V; Manguán-García C; Cejas P; López-Ríos F; Paz-Ares L; de CastroCarpeño J; Nistal M; Belda-Iniesta C; Perona R
    Oncogene; 2010 Mar; 29(11):1681-90. PubMed ID: 20023704
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DNA methyltransferase 1 as a predictive biomarker and potential therapeutic target for chemotherapy in gastric cancer.
    Mutze K; Langer R; Schumacher F; Becker K; Ott K; Novotny A; Hapfelmeier A; Höfler H; Keller G
    Eur J Cancer; 2011 Aug; 47(12):1817-25. PubMed ID: 21458988
    [TBL] [Abstract][Full Text] [Related]  

  • 8. GSTP1 determines cis-platinum cytotoxicity in gastric adenocarcinoma MGC803 cells: regulation by promoter methylation and extracellular regulated kinase signaling.
    Zhang Y; Qu X; Jing W; Hu X; Yang X; Hou K; Teng Y; Zhang J; Liu Y
    Anticancer Drugs; 2009 Mar; 20(3):208-14. PubMed ID: 19396019
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of molecular subtypes of gastric cancer with different responses to PI3-kinase inhibitors and 5-fluorouracil.
    Lei Z; Tan IB; Das K; Deng N; Zouridis H; Pattison S; Chua C; Feng Z; Guan YK; Ooi CH; Ivanova T; Zhang S; Lee M; Wu J; Ngo A; Manesh S; Tan E; Teh BT; So JB; Goh LK; Boussioutas A; Lim TK; Flotow H; Tan P; Rozen SG
    Gastroenterology; 2013 Sep; 145(3):554-65. PubMed ID: 23684942
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ankyrin repeat domain 1, ANKRD1, a novel determinant of cisplatin sensitivity expressed in ovarian cancer.
    Scurr LL; Guminski AD; Chiew YE; Balleine RL; Sharma R; Lei Y; Pryor K; Wain GV; Brand A; Byth K; Kennedy C; Rizos H; Harnett PR; deFazio A
    Clin Cancer Res; 2008 Nov; 14(21):6924-32. PubMed ID: 18980987
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of neurofilament light polypeptide in head and neck cancer chemoresistance.
    Chen B; Chen J; House MG; Cullen KJ; Nephew KP; Guo Z
    Mol Cancer Res; 2012 Mar; 10(3):305-15. PubMed ID: 22246235
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhanced expression of nuclear factor I/B in oxaliplatin-resistant human cancer cell lines.
    Kashiwagi E; Izumi H; Yasuniwa Y; Baba R; Doi Y; Kidani A; Arao T; Nishio K; Naito S; Kohno K
    Cancer Sci; 2011 Feb; 102(2):382-6. PubMed ID: 21087353
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel mechanisms of platinum drug resistance identified in cells selected for resistance to JM118 the active metabolite of satraplatin.
    Samimi G; Kishimoto S; Manorek G; Breaux JK; Howell SB
    Cancer Chemother Pharmacol; 2007 Feb; 59(3):301-12. PubMed ID: 16770583
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overexpression of IFITM1 has clinicopathologic effects on gastric cancer and is regulated by an epigenetic mechanism.
    Lee J; Goh SH; Song N; Hwang JA; Nam S; Choi IJ; Shin A; Kim IH; Ju MH; Jeong JS; Lee YS
    Am J Pathol; 2012 Jul; 181(1):43-52. PubMed ID: 22609115
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification and functional analysis of genes which confer resistance to cisplatin in tumor cells.
    Wu ZZ; Lu HP; Chao CC
    Biochem Pharmacol; 2010 Jul; 80(2):262-76. PubMed ID: 20361941
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Proteomics-based identification of secreted protein dihydrodiol dehydrogenase 2 as a potential biomarker for predicting cisplatin efficacy in advanced NSCLC patients.
    Kuang P; Zhou C; Li X; Ren S; Li B; Wang Y; Li J; Tang L; Zhang J; Zhao Y
    Lung Cancer; 2012 Aug; 77(2):427-32. PubMed ID: 22534668
    [TBL] [Abstract][Full Text] [Related]  

  • 17. WNT6 is a novel target gene of caveolin-1 promoting chemoresistance to epirubicin in human gastric cancer cells.
    Yuan G; Regel I; Lian F; Friedrich T; Hitkova I; Hofheinz RD; Ströbel P; Langer R; Keller G; Röcken C; Zimmermann W; Schmid RM; Ebert MP; Burgermeister E
    Oncogene; 2013 Jan; 32(3):375-87. PubMed ID: 22370641
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An integrative approach identified genes associated with drug response in gastric cancer.
    Zhou J; Yong WP; Yap CS; Vijayaraghavan A; Sinha RA; Singh BK; Xiu S; Manesh S; Ngo A; Lim A; Ang C; Xie C; Wong FY; Lin SJ; Wan WK; Tan IB; Flotow H; Tan P; Lim KH; Yen PM; Goh LK
    Carcinogenesis; 2015 Apr; 36(4):441-51. PubMed ID: 25742747
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oxaliplatin induces drug resistance more rapidly than cisplatin in H69 small cell lung cancer cells.
    Stordal BK; Davey MW; Davey RA
    Cancer Chemother Pharmacol; 2006 Aug; 58(2):256-65. PubMed ID: 16283310
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Concentration-dependent collateral sensitivity of cisplatin-resistant gastric cancer cell sublines.
    Xu H; Choi SM; An CS; Min YD; Kim KC; Kim KJ; Choi CH
    Biochem Biophys Res Commun; 2005 Mar; 328(2):618-22. PubMed ID: 15694393
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.